Eurazeo-managed Nov Santé Actions Non Cotées Fund completed a €16m investment in Kinvent.

Eurazeo-managed Nov Santé Actions Non Cotées Fund, a private equity fund, completed a €16m investment in Kinvent, a biomechanical solution for performance, rehabilitation, and scientific research company. “Our teams are delighted to welcome on board a leading investor such as Eurazeo in order to build together the world’s leading supplier of connected solutions for physiotherapists and sport practitioners. We are at a key stage in our development, operating in a rapidly growing market, and we truly believe that the Nov Santé team will be able to help Kinvent develop even further by leveraging its understanding of the healthcare market and its wide in-house expertise,” Athanase Kollias, Kinvent CEO and Founder.